To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Naloxone
Thursday 25th April 2024

Asked by: Charlotte Nichols (Labour - Warrington North)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the potential merits of creating a national naloxone programme.

Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)

Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.

Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.

The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.

The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.


Written Question
Naloxone
Thursday 25th April 2024

Asked by: Charlotte Nichols (Labour - Warrington North)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what her planned timetable is for publishing a response to her Department's consultation on Expanding access to naloxone.

Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)

Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.

Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.

The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.

The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.


Written Question
Naloxone
Thursday 25th April 2024

Asked by: Charlotte Nichols (Labour - Warrington North)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the availability of naloxone across England.

Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)

Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.

Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.

The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.

The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.


Written Question
Naloxone
Thursday 25th April 2024

Asked by: Charlotte Nichols (Labour - Warrington North)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether she is taking steps to increase awareness of naloxone.

Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)

Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.

Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.

The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.

The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.


Written Question
Smoking
Thursday 25th April 2024

Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking with Cabinet colleagues to help ensure that lobbying by the tobacco industry does not undermine future public health policies aimed at reducing smoking rates.

Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)

Smoking is responsible for approximately 80,000 deaths a year in the United Kingdom, and causes around one in four cancer deaths in the UK. It also costs our country £17 billion a year, and puts a huge burden on the National Health Service. Smoking is an addiction, and there is no liberty in addiction. It causes harm to not only the smoker, but to society as a whole. That is why we have introduced the Tobacco and Vapes Bill to create the first smokefree generation, and enable us to further crack down on youth vaping. The Tobacco and Vapes Bill is available at the following link:

https://bills.parliament.uk/bills/3703

The UK is a party to the World Health Organization Framework Convention on Tobacco Control, and under Article 5.3 has an obligation to protect the development of public health policy from the vested interests of the tobacco industry. As a world leader in tobacco control, the Government takes this commitment very seriously. In 2023, the Department published guidance for Government engagement with the tobacco industry, which is available at the following link:

https://www.gov.uk/government/publications/protocol-for-engagement-with-stakeholders-with-links-to-the-tobacco-industry/guidance-for-government-engagement-with-the-tobacco-industry

The Department regularly publishes correspondence from, or to, those with links to the tobacco industry, and it is available at the following link:

https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view/394794557


Written Question
Smoking
Thursday 25th April 2024

Asked by: Rachael Maskell (Labour (Co-op) - York Central)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the number of people participating in smoking cessation programmes.

Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)

Smoking is the number one entirely preventable cause of ill-health, disability and death in this country. It is responsible for 80,000 yearly deaths in the United Kingdom and one in four of all UK cancer deaths. It costs our country £17 billion a year, £14 billion of which is through lost productivity alone. It puts a huge pressure on the National Health Service and social care, costing over £3 billion a year. Quitting smoking is the best thing a smoker can do for their health and smokers are three times as likely to succeed with stop smoking services (SSS) when compared to an unsupported quit attempt.

As announced in Stopping the start: our new plan to create a smokefree generation, published in October 2023, the Government is investing an additional £70 million per year for five years to support local authority-led SSS, around doubling current spend and supporting 360,000 people to set a quit date each year. To support engagement with SSS, and increase motivation to quit, we are spending an additional £15 million per year to fund national anti-smoking campaigns. We are also investing up to £45 million over two years to roll out our national ‘Swap to Stop’ scheme and establishing a financial incentives scheme to help pregnant smokers and their partners quit smoking with smoking cessation support.

Vaping is never recommended for children, and carries the potential harms of future addiction while their lungs and brains are still developing. The health advice is clear, vapes can be an effective tool to help smokers quit, but young people and those who have never smoked should not vape, or be encouraged to vape.


Written Question

Question Link

Thursday 25th April 2024

Asked by: Christine Jardine (Liberal Democrat - Edinburgh West)

Question to the Department for Levelling Up, Housing & Communities:

To ask the Secretary of State for Levelling Up, Housing and Communities, what recent discussions he has had with Cabinet colleagues on the potential impact of the UK's constitutional arrangements on the strength of the Union.

Answered by Felicity Buchan - Parliamentary Under Secretary of State (Department for Levelling Up, Housing and Communities)

In line with the longstanding practice of successive administrations, Cabinet discussions are confidential, and details are not normally disclosed. But I will say that the United Kingdom is one of the world’s most successful political and economic unions. When we work together as one United Kingdom, we are safer, stronger and more prosperous.


Written Question
Suicide: Coastal Areas
Thursday 25th April 2024

Asked by: Lord Hunt of Kings Heath (Labour - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government, with reference to research by Christine Camacho and Luke Munford at the University of Manchester showing that deaths from drugs, alcohol and suicide are higher in northern and coastal local authorities, what steps they are taking to address that regional inequality.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Levelling Up the United Kingdom white paper sets out the Government’s ambition to improve living standards and wellbeing across the UK, invest in communities, and improve public services. It sets mutually reinforcing levelling up missions to focus Government action, including a health mission to narrow the gap in healthy life expectancy by 2030, and increase healthy life expectancy by five years by 2035.

The Government has published a 10-year drug strategy and is investing an extra £532 million between 2022/23 to 2024/25 to improve drug and alcohol treatment and recovery services. This funding is being used by local authorities to create places for an additional 54,500 people in drug and alcohol treatment services and bolster the workforce, seeking to prevent nearly 1,000 deaths. This funding is being targeted to areas of highest need first.

The Department is increasingly focusing on supporting local areas, including better meeting the needs of vulnerable groups. Current work includes: providing targeted support to local areas; enhancing data tools to better inform local needs assessments; supporting workforce development; implementation of the commissioning quality standard; and sharing good practice. Implementation support will adapt over the course of the 10-year strategy in response to need, to ensure we reach the drug strategy goals.

We also published our new Suicide Prevention Strategy for England in September 2023, setting out the actions we will take to save lives and reduce suicides within the next few years, and have set out our intention in the strategy to write guidance for local areas to support them in aligning their own strategies with the national strategy. We have also established a £10 million Suicide Prevention Grant Fund to run from 2023 to March 2025, and on 4 March 2024 we announced the 79 organisations across the country that have been allocated funding. We have also launched a new nationwide, near real-time suspected suicide surveillance system, that will improve the early detection of, and timely action to, address changes in suicide rates or trends.


Written Question
Mental Health: Equality
Thursday 25th April 2024

Asked by: Lord Hunt of Kings Heath (Labour - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government, with reference to research by Christine Camacho and Luke Munford at the University of Manchester, what steps they are taking to reduce regional inequalities in what those researchers refer to as "Deaths of Despair".

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Levelling Up the United Kingdom white paper sets out the Government’s ambition to improve living standards and wellbeing across the UK, invest in communities, and improve public services. It sets mutually reinforcing levelling up missions to focus Government action, including a health mission to narrow the gap in healthy life expectancy by 2030, and increase healthy life expectancy by five years by 2035.

The Government has published a 10-year drug strategy and is investing an extra £532 million between 2022/23 to 2024/25 to improve drug and alcohol treatment and recovery services. This funding is being used by local authorities to create places for an additional 54,500 people in drug and alcohol treatment services and bolster the workforce, seeking to prevent nearly 1,000 deaths. This funding is being targeted to areas of highest need first.

The Department is increasingly focusing on supporting local areas, including better meeting the needs of vulnerable groups. Current work includes: providing targeted support to local areas; enhancing data tools to better inform local needs assessments; supporting workforce development; implementation of the commissioning quality standard; and sharing good practice. Implementation support will adapt over the course of the 10-year strategy in response to need, to ensure we reach the drug strategy goals.

We also published our new Suicide Prevention Strategy for England in September 2023, setting out the actions we will take to save lives and reduce suicides within the next few years, and have set out our intention in the strategy to write guidance for local areas to support them in aligning their own strategies with the national strategy. We have also established a £10 million Suicide Prevention Grant Fund to run from 2023 to March 2025, and on 4 March 2024 we announced the 79 organisations across the country that have been allocated funding. We have also launched a new nationwide, near real-time suspected suicide surveillance system, that will improve the early detection of, and timely action to, address changes in suicide rates or trends.


Written Question
Pregnancy: Smoking
Thursday 25th April 2024

Asked by: Rachael Maskell (Labour (Co-op) - York Central)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to encourage pregnant women to undertake smoking cessation programmes.

Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)

Smoking is the number one entirely preventable cause of ill-health, disability, and death in this country. It is responsible for 80,000 yearly deaths in the United Kingdom, and one in four of all UK cancer deaths. Smoking in pregnancy increases the risk of stillbirth, miscarriage, and sudden infant death.

As set out in Stopping the Start: our new plan to create a smokefree generation, we are establishing a financially incentivised scheme to help pregnant smokers and their partners to quit smoking, with smoking cessation support. This evidence-based intervention will encourage pregnant women to give up smoking, and remain smokefree throughout pregnancy and beyond, helping to improve the health and wellbeing of both mother and baby.

The objective is to have all maternity trusts that wish to participate in the scheme signed up by the end of 2024, so that all pregnant women who smoke in participating areas will be offered the opportunity to join the incentive scheme by December 2024.

This financial incentive scheme builds upon the NHS Long Term Plan’s ambition to ensure that all pregnant smokers can access behavioural support to quit from within maternity services, as well as additional funding for mass marketing campaigns on stopping smoking.